Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $190 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $190.
September 14, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating on Alnylam Pharmaceuticals and maintained a price target of $190.
The reiteration of a Neutral rating by Cantor Fitzgerald indicates that the analyst believes the stock is fairly valued at current levels. The maintained price target of $190 suggests that the analyst does not foresee significant price movement in the short term. This could lead to a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100